SCHEMBL22340951

SCHEMBL22340951

CCCC(C)N(Cc1ccc(Cl)cc1)c1ccc(OC)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2A1 Q16548 2/20 0.47
CNR2 P34972 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HTT P42858 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
APLNR P35414 2/20 0.38
FPR2 P25090 1/20 0.38
UTS2R Q9UKP6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20871412 0.93 HTT (0.42) CNR2SMN1; SMN2ALDH1A1HTTAPLNR
SCHEMBL29336141 0.89 BCL2A1 (0.49) BCL2A1CNR2SMN1; SMN2MEN1KMT2A
SCHEMBL20871164 0.88 CNR1 (0.45) CNR2SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL22340948 0.88 CNR1 (0.45) CNR2SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL22340950 0.86 KMT2A (0.45) CNR2SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL22340961 0.86 APP (0.44) CNR2SMN1; SMN2ALDH1A1HTTAPLNR
SCHEMBL29336228 0.86 KMT2A (0.41) SMN1; SMN2MEN1KMT2AALDH1A1HTT
SCHEMBL29335354 0.84 BCL2A1 (0.52) BCL2A1CNR2SMN1; SMN2MEN1KMT2A
SCHEMBL22340943 0.84 QPCT (0.45) SMN1; SMN2MEN1KMT2AHTTAPLNR
SCHEMBL22340952 0.84 CYP19A1 (0.44) CNR2MEN1KMT2ATDP1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3707132-B1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES UNIV PARIS SACLAY (FR) 2024-07-17 EP disclosed
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines Universite Paris-Saclay (FR) 2021-06-15 US disclosed
US-20200255369-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES Universite Paris-Saclay (FR) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255369-A1 NEW METHOD FOR THE SYNTHESIS OF UNSYMMETRICAL TERTIARY AMINES ADH1C, ADH1A, ADH5 BCL2A1 4363/4885CNR2 1633/4885SMN1; SMN2 2857/4885
US-11034646-B2 Method for the synthesis of unsymmetrical tertiary amines ADH1C, PNMT, ADH1A BCL2A1 4352/4885CNR2 2182/4885SMN1; SMN2 2752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.